Skip to main content
. 2014 Aug 27;9(1):204–217. doi: 10.1016/j.molonc.2014.08.001

Figure 4.

Figure 4

ATM inhibitors in BRCA1 deficient and BRCA1 proficient cells. A1. Clonogenic survival assays in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with KU55933. A2. ↠H2AX immunohistochemistry in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with KU55933. A3. FACS analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with KU55933. A4. Annexin V flow cytometric analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with KU55933.B1. Clonogenic survival assays in MDA‐MB‐436 and MCF7 cells treated with KU55933. B2. ↠H2AX immunohistochemistry in MDA‐MB‐436 and MCF7 cells treated with KU55933. B3. FACS analysis in MDA‐MB‐436 and MCF7 cells treated with KU55933. B4. Annexin V flow cytometric analysis in MDA‐MB‐436 and MCF7 cells treated with KU55933. Inhibitors were added at the indicated concentrations (see Methods for details). C1. Clonogenic survival assays in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in combination with KU55933. C2. ↠H2AX immunohistochemistry in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in combination with KU55933. C3. FACS analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in combination with KU55933. C4. Annexin V flow cytometric analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in combination with KU55933. D1. Clonogenic survival assays in MDA‐MB‐436 and MCF7 cells treated with cisplatin alone or in combination with KU55933. D2. ↠H2AX immunohistochemistry in MDA‐MB‐436 and MCF7 cells treated with cisplatin alone or in combination with KU55933. D3. FACS analysis in MDA‐MB‐436 and MCF7 cells treated with cisplatin alone or in combination with KU55933. D4. Annexin V flow cytometric analysis in MDA‐MB‐436 and MCF7 cells treated with cisplatin alone or in combination with KU55933. *p < 0.05, **p < 0.01.